Evidence map›Paper›PMID 35281113›Full record

ArticleFrontiers in cell and developmental biology2022

Applicability of Anticancer Drugs for the Triple-Negative Breast Cancer Based on Homologous Recombination Repair Deficiency.

Gaoming Liao, Yiran Yang, Aimin Xie, Zedong Jiang, Jianlong Liao, Min Yan, Yao Zhou, Jiali Zhu, Jing Hu, Yunpeng Zhang and 2 more

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Frontiers in cell and developmental biology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
0.5field-weighted citation impact, top 35% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 8 citations in OpenAlex.

  1. Article
  2. Review
  3. Article
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors at 2 institutions in 1 country.

Gaoming LiaoCollege of Bioinformatics Science and Technology, Harbin Medical University, Harbin, China.
Yiran YangCollege of Bioinformatics Science and Technology, Harbin Medical University, Harbin, China.
Aimin XieCollege of Bioinformatics Science and Technology, Harbin Medical University, Harbin, China.
Zedong JiangCollege of Bioinformatics Science and Technology, Harbin Medical University, Harbin, China.
Jianlong LiaoCollege of Bioinformatics Science and Technology, Harbin Medical University, Harbin, China.
Min YanCollege of Bioinformatics Science and Technology, Harbin Medical University, Harbin, China.
Yao ZhouCollege of Bioinformatics Science and Technology, Harbin Medical University, Harbin, China.
Jiali ZhuCollege of Bioinformatics Science and Technology, Harbin Medical University, Harbin, China.
Jing HuCollege of Bioinformatics Science and Technology, Harbin Medical University, Harbin, China.
Yunpeng ZhangCollege of Bioinformatics Science and Technology, Harbin Medical University, Harbin, China.
Yun XiaoCollege of Bioinformatics Science and Technology, Harbin Medical University, Harbin, China.
Xia LiCollege of Bioinformatics Science and Technology, Harbin Medical University, Harbin, China.
Harbin Medical University · CNHainan Medical University · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Triple-negative breast cancer (TNBC) is a highly aggressive disease with historically poor outcomes, primarily due to the lack of effective targeted therapies. Here, we established a drug sensitivity prediction model based on the homologous recombination deficiency (HRD) using 83 TNBC patients from TCGA. Through analyzing the effect of HRD status on response efficacy of anticancer drugs and elucidating its related mechanisms of action, we found rucaparib (PARP inhibitor) and doxorubicin (anthracycline) sensitive in HR-deficient patients, while paclitaxel sensitive in the HR-proficient. Further, we identified a HRD signature based on gene expression data and constructed a transcriptomic HRD score, for analyzing the functional association between anticancer drug perturbation and HRD. The results revealed that CHIR99021 (GSK3 inhibitor) and doxorubicin have similar expression perturbation patterns with HRD, and talazoparib (PARP inhibitor) could kill tumor cells by reversing the HRD activity. Genomic characteristics indicated that doxorubicin inhibited tumor cells growth by hindering the process of DNA damage repair, while the resistance of cisplatin was related to the activation of angiogenesis and epithelial-mesenchymal transition. The negative correlation of HRD signature score could interpret the association of doxorubicin pIC50 with worse chemotherapy response and shorter survival of TNBC patients. In summary, these findings explain the applicability of anticancer drugs in TNBC and underscore the importance of HRD in promoting personalized treatment development.

Indexed as

connectivity map (CMap)drug sensitivityhomologous recombination repair deficiency (HRD)pharmacogenomicstriple-negative breast cancer (TNBC)

Identifiers

PMID35281113
PMCPMC8913497
OpenAlexW4214761175

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.